Overexpression of p65 attenuates celecoxib-induced cell death in MDA-MB-231 human breast cancer cell line

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Wang, Ling ^a   Kang, Fubiao ^b   Li, Jie ^a   Zhang, Jing ^a   Shan, Baoen ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b BETHUNE INTERNATIONAL PEACE HOSPITAL   (China)

Author keywords

Apoptosis; Breast cancer; Celecoxib; p65

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CASPASE 3; CASPASE 9; CELECOXIB; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LUCIFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE B; SURVIVIN; SYNAPTOTAGMIN I; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; BREAST CANCER; CELL CYCLE G0 PHASE; CELL CYCLE REGULATION; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; DOWN REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; HUMAN; HUMAN CELL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REPORTER GENE; UPREGULATION; WESTERN BLOTTING;

EID: 84873699578     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-14     Document Type: Article

References (38)

1. Zheng S, Bai JQ, Li J, Fan JH, Pang Y, Song QK, Huang R, Yang HJ, Xu F, Lu N, Qiao YL. The pathologic characteristics of breast cancer in China and its shift during 1999-2008: A national-wide multicenter cross-sectional image over 10 years. Int J Cancer 2012, Epub ahead of print.
2. Howard JH, Bland KI. Current management and treatment strategies for breast cancer. Curr Opin Obstet Gynecol 2012, 24(1):44-48. 10.1097/GCO.0b013e32834da4b1, 22123219.
3. Harris RE, Alshafie GA, Bou-Issa H, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase 2 inhibitor. Cancer Res 2000, 60(8):2101-2103.
4. Basu GD, Pathangey LB, Tinder TL, Lagioia M, Gendler SJ, Mukherjee P. Cyclooxygenase-2 inhibitor induces apoptosis in breast cancer cells in an in vivo model of spontaneous metastatic breast cancer. Mol Cancer Res 2004, 2(11):632-642.
5. Grosch S, Maier TJ, Schiffmann S, Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J Natl Cancer Inst 2006, 98(11):736-747. 10.1093/jnci/djj206, 16757698.
6. Kang HK, Lee E, Pyo H, Lim SJ. Cyclooxygenase-independent down-regulation of multidrug resistance-associated protein-1 expression by celecoxib in human lung cancer cells. Mol Cancer Ther 2005, 4(9):1358-1363. 10.1158/1535-7163.MCT-05-0139, 16170027.
7. Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of Ikappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004, 173(3):2011-2022.
8. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001, 15(14):2742-2744.
9. Chen S, Cao W, Yue P, Hao C, Khuri FR, Sun SY. Celecoxib promotes c-FLIP degradation through Akt-independent inhibition of GSK3. Cancer Res 2011, 71(19):6270-6281. 10.1158/0008-5472.CAN-11-0838, 3185138, 21868755.
10. Zaric J, Joseph JM, Tercier S, Sengstag T, Ponsonnet L, Delorenzi M, Ruegg C. Identification of MAGI1 as a tumor-suppressor protein induced by cyclooxygenase-2 inhibitors in colorectal cancer cells. Oncogene 2012, 31(1):48-59. 10.1038/onc.2011.218, 21666716.
11. Liu Y, Liu A, Li H, Li C, Lin J. Celecoxib inhibits interleukin-6/interleukin-6 receptor-induced JAK2/STAT3 phosphorylation in human hepatocellular carcinoma cells. Cancer Prev Res (Phila) 2011, 4(8):1296-1305.
12. Chen L, He Y, Huang H, Liao H, Wei W. Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study. Med Oncol 2008, 25(2):161-171. 10.1007/s12032-007-9015-1, 18172786.
13. Basu GD, Pathangey LB, Tinder TL, Gendler SJ, Mukherjee P. Mechanisms underlying the growth inhibitory effects of the cyclo-oxygenase-2 inhibitor celecoxib in human breast cancer cells. Breast Cancer Res 2005, 7(4):R422-R435. 10.1186/bcr1019, 1175053, 15987447.
14. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, Pardee AB. The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci U S A 2001, 98(18):10386-10391. 10.1073/pnas.151257998, 56970, 11517301.
15. Singh S, Shi Q, Bailey ST, Palczewski MJ, Pardee AB, Iglehart JD, Biswas DK. Nuclear factor-kappaB activation: a molecular therapeutic target for estrogen receptor-negative and epidermal growth factor receptor family receptor-positive human breast cancer. Mol Cancer Ther 2007, 6(7):1973-1982. 10.1158/1535-7163.MCT-07-0063, 17620428.
16. Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012, 26(3):203-234. 10.1101/gad.183434.111, 3278889, 22302935.
17. Perkins ND. The diverse and complex roles of NF-kappaB subunits in cancer. Nat Rev Cancer 2012, 12(2):121-132.
18. O'Shea JM, Perkins ND. Regulation of the RelA (p65) transactivation domain. Biochem Soc Trans 2008, 36(Pt 4):603-608.
19. Montagut C, Tusquets I, Ferrer B, Corominas JM, Bellosillo B, Campas C, Suarez M, Fabregat X, Campo E, Gascon P, Serrano S, Fernandez PL, Rovira A, Albanell J. Activation of nuclear factor-kappa B is linked to resistance to neoadjuvant chemotherapy in breast cancer patients. Endocr Relat Cancer 2006, 13(2):607-616. 10.1677/erc.1.01171, 16728586.
20. Wang L, Liu LH, Shan BE, Zhang C, Sang MX, Li J. [Celecoxib promotes apoptosis of breast cancer cell line MDA-MB-231 through down-regulation of the NF-kappaB pathway]. Ai Zheng 2009, 28(6):569-574.
21. Meng F, Liu L, Chin PC, D'Mello SR. Akt is a downstream target of NF-kappa B. J Biol Chem 2002, 277(33):29674-29680. 10.1074/jbc.M112464200, 12052823.
22. Meng F, D'Mello SR. NF-kappaB stimulates Akt phosphorylation and gene expression by distinct signaling mechanisms. Biochim Biophys Acta 2003, 1630(1):35-40. 10.1016/j.bbaexp.2003.09.001, 14580677.
23. Haberkorn U, Markert A, Mier W, Askoxylakis V, Altmann A. Molecular imaging of tumor metabolism and apoptosis. Oncogene 2011, 30(40):4141-4151. 10.1038/onc.2011.169, 21577202.
24. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 2012, 11(2):109-124. 10.1038/nrd3627, 22293567.
25. Jin HR, Jin X, Dat NT, Lee JJ. Cucurbitacin B suppresses the transactivation activity of RelA/p65. J Cell Biochem 2011, 112(6):1643-1650. 10.1002/jcb.23078, 21344491.
26. Bavi P, Uddin S, Bu R, Ahmed M, Abubaker J, Balde V, Qadri Z, Ajarim D, Al-Dayel F, Hussain AR, Al-Kuraya KS. The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). J Pathol 2011, 224(3):355-366. 10.1002/path.2864, 21506127.
27. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS. Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets 2011, 12(7):1082-1093. 10.2174/138945011795677764, 21443470.
28. Madrid LV, Mayo MW, Reuther JY, Baldwin AS. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-kappa B through utilization of the Ikappa B kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001, 276(22):18934-18940. 10.1074/jbc.M101103200, 11259436.
29. Campbell KJ, Rocha S, Perkins ND. Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol Cell 2004, 13(6):853-865. 10.1016/S1097-2765(04)00131-5, 15053878.
30. Anto RJ, Maliekal TT, Karunagaran D. L-929 cells harboring ectopically expressed RelA resist curcumin-induced apoptosis. J Biol Chem 2000, 275(21):15601-15604. 10.1074/jbc.C000105200, 10747850.
31. Collett GP, Campbell FC. Overexpression of p65/RelA potentiates curcumin-induced apoptosis in HCT116 human colon cancer cells. Carcinogenesis 2006, 27(6):1285-1291. 10.1093/carcin/bgi368, 16497702.
32. Yu HG, Yu LL, Yang Y, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F. Increased expression of RelA/nuclear factor-kappa B protein correlates with colorectal tumorigenesis. Oncology 2003, 65(1):37-45. 10.1159/000071203, 14586145.
33. Ricca A, Biroccio A, Trisciuoglio D, Cippitelli M, Zupi G, Del BD. relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. Br J Cancer 2001, 85(12):1914-1921. 10.1054/bjoc.2001.2174, 2364001, 11747334.
34. Zou T, Rao JN, Guo X, Liu L, Zhang HM, Strauch ED, Bass BL, Wang JY. NF-kappaB-mediated IAP expression induces resistance of intestinal epithelial cells to apoptosis after polyamine depletion. Am J Physiol Cell Physiol 2004, 286(5):C1009-C1018.
35. Danial NN. BCL-2 family proteins: critical checkpoints of apoptotic cell death. Clin Cancer Res 2007, 13(24):7254-7263. 10.1158/1078-0432.CCR-07-1598, 18094405.
36. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005, 102(39):13944-13949. 10.1073/pnas.0506654102, 1236577, 16166262.
37. Pietras EM, Warr MR, Passegue E. Cell cycle regulation in hematopoietic stem cells. J Cell Biol 2011, 195(5):709-720. 10.1083/jcb.201102131, 3257565, 22123859.
38. Uhlmann F, Bouchoux C, López-Avilés S. A quantitative model for cyclin-dependent kinase control of the cell cycle: revisited. Philos Trans R Soc Lond B Biol Sci 2011, 366(1584):3572-3583. 10.1098/rstb.2011.0082, 3203462, 22084384.